3-(4-Cyclopropyl-6-methylpyridin-2-yl)propan-1-ol, 1g

N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide, 98%, 50mg

2-butyl-3-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one, 95%, 1g

rEGCase II1vial

6-Phenyl-pyridine-3-sulfonic acid amide, 95.0%, 1g

3-[2-(propan-2-yl)-1H-imidazol-1-yl]propanoic acid hydrochloride, 97%, 10g

10-(Benzyloxy)-10-oxodecanoic acid, 97%, 25g

1-Bromo-8-fluoronaphthalene, 95%, 10g

4-Methoxybenzo[d]thiazole, 95.0%, 5g

1,1'-[Methylenebis(2,6-diethyl-4,1-phenylene)]bis[3-(2-nitrophenyl)urea]>98.0%(HPLC)(N)1g

(R)-2-(tert-butyl)-2,3-dihydrobenzo[d]imidazo[2,1-b]thiazole, 97%, 250mg

3,6-Dichloro-2-nitroaniline, 25mg

4-(Difluoromethoxy)benzyl bromide, 99.0%, 25g